No comments yet. Be the first to say something!
📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. Structured synopses of each individual clinical study in the program.
Why it exists. Before a reviewer opens a full study report in Module 5, Module 2.7.6 offers a standardized one-to-few-page synopsis of each study — design, population, and key results — as a quick reference and index.
How it is produced here. It contains no new data. It is a distillation — it gathers, summarizes, and cross-references the underlying study reports and datasets into the shorter form a regulator reads first.
Format & governing standard. ICH M4E(R2) §2.7.6
| Field | Value |
|---|---|
| Document ID | M276 |
| Version | 1.0 |
| Compound | GLPI-103 (GLP-1/APJ dual agonist) |
| Standard | ICH M4E(R2) §2.7.6 |
| Confidentiality | Confidential |
One-page synopsis per clinical study. Pivotal figures trace to
outputs/(reconciled); early-phase[MOCK].
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-29 | Clinical | Initial synopses |
Randomized, DB, placebo-controlled single ascending dose in 40 healthy volunteers (5 cohorts × 8; 6:2). Objectives: safety, tolerability, PK; PD (plasma apelin). Result [MOCK]: no dose-limiting toxicity; ~dose-proportional PK; long half-life supporting QW dosing.
Randomized, DB, placebo-controlled multiple ascending dose, ≤12 weeks, in 40 overweight/obese adults with T2DM/prediabetes (4 cohorts × 10; 8:2). Result [MOCK]: titration-manageable GI AEs; dose-dependent HbA1c (−0.8%) and weight (−3 kg); favourable NT-proBNP/hsCRP.
Randomized, DB, placebo-controlled, 4 arms (PBO + low/med/high), 24 weeks, 240 T2DM on metformin. Primary: HbA1c CFB. Result [MOCK]: monotonic dose–response; dose-dependent weight loss; GI AEs dose-related. Supported Phase 3 doses (Gate-3 decision; PM-002).
Randomized, DB, double-dummy, active-controlled (vs oral semaglutide), 1:1:1, 52 weeks, 900 randomized to target (IV 300 / Oral 301 / Sema 299; 1,700 screened) T2DM inadequately controlled on metformin. Primary: HbA1c CFB at Week 52.